查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2118838

血糖監測系統：市場洞察、競爭格局及市場預測 - 2034 年

Blood Glucose Monitoring Systems - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

概述：

  • 全球血糖監測系統市場預計到 2025 年將達到 130.6 億美元，到 2034 年將達到 255 億美元。
  • 在 2026 年至 2034 年的預測期內，市場預計將以 7.72% 的複合年成長率成長，這得益於糖尿病和葡萄糖耐受不良等文明病的日益普遍、新產品的推出和批准的增加，以及對微創監測技術的需求不斷成長。
  • 按產品類型分類，預計到 2025 年，連續血糖監測系統細分市場將佔 62% 的市場佔有率，從而推動血糖監測系統市場的發展。
  • 就測量方法而言，預計到 2025 年，穿戴式裝置將引領血糖監測系統市場，佔 58% 的市場佔有率。
  • 按最終用戶分類，預計到 2025 年，居家照護環境細分市場將佔血糖監測系統市場佔有率的 60%，從而推動市場成長。
  • 到 2025 年，北美將佔血糖監測系統市場最大的佔有率，達到 38%，但預計到 2034 年，亞太地區將實現最快的成長。

血糖監測系統是一種用於家庭和醫療機構的設備，用於測量和監測血糖水平，使糖尿病患者或葡萄糖耐受不良者能夠了解自身的血糖值，並據此調整飲食、運動和藥物治療。本市場按設備類型、使用方式和施行地點進行細分。依產品類型分類，可分為「自我監測血糖系統」及「連續血糖監測系統」。 「自我監測血糖系統」是指使用者將毛細血管血滴在試紙上，血糖儀讀取讀數；「連續血糖監測系統」是指植入皮下的小型感測器測量組織液中的葡萄糖水平並持續更新讀數。依使用方式分類，可分為穿戴式裝置和非穿戴式裝置。穿戴式裝置是基於感測器的連續測量和長期配戴系統，主要佩戴在身上；非穿戴裝置則包括血糖儀和試紙，主要用於間歇性自我監測。依最終用戶分類，可分為醫院、居家照護機構以及其他需要測量和管理血糖值的場所。受全球糖尿病盛行率上升、持續血糖監測加速普及、感測器精度、佩戴時間、連接性和人工智慧等技術的不斷進步，以及血糖數據與數位健康平台和自動胰島素給藥的整合等因素推動，該市場正在迅速擴張。

血糖監測系統市場的主要成長促進因素

  • 在全球範圍內，第1型糖尿病、第2型糖尿病和妊娠期糖尿病的盛行率正在上升。根據國際糖尿病聯盟（IDF）的數據，2021年全球有5.37億成年人患有糖尿病，預計到2030年這一數字將達到6.43億，到2045年將達到7.83億。
  • 持續血糖監測的普及速度正在加快，尤其是在胰島素依賴型患者中，因為能夠進行即時和間歇掃描的系統可以提供更高的準確性、便利性和治療依從性。
  • 持續的技術進步包括提高感測器精度、延長佩戴時間、智慧型手機連接、基於雲端的數據共用、人工智慧驅動的預測分析以及微創、無針感測器。
  • 這主要歸功於人們對早期診斷和自我管理意識的提高。鼓勵自我監測血糖值的教育活動、預防保健計畫和定期監測都是促成因素。
  • 主要市場優惠的保險報銷政策。在美國、歐洲和日本，血糖試紙、血糖儀和持續血糖監測系統的保險覆蓋範圍減少了患者的自付費用，並促進了這些產品的普及。
  • 老年人口數量不斷增加。由於老年人糖尿病盛行率較高，且需要持續監測，因此自我監測和持續血糖監測的使用率都在上升。
  • 數位健康平台（包括基於雲端的資料共用、遠端患者監護、遠端醫療和醫生儀表板）的整合，正在提高設備在慢性病管理中的價值。

推動血糖監測系統市場成長的因素

市場促進因素

全球糖尿病盛行率不斷上升

血糖監測系統市場的主要驅動力是糖尿病盛行率的快速成長。這是因為糖尿病患者人數直接決定了構成該市場的血糖儀、試紙和連續血糖監測系統的需求。 1型糖尿病、第2型糖尿病和妊娠期糖尿病發生率的上升是推動需求成長的最主要因素。隨著病患人數的增加，各類醫療設備的銷售也隨之成長，其規模與趨勢都極為顯著。根據國際糖尿病聯盟（IDF）的數據，2021年，全球20至79歲的成年人中有5.37億人患有糖尿病，約佔總人口的十分之一。此外，預計到2030年，這一數字將增加至6.43億，到2045年將達到7.83億，其中超過75%的糖尿病患者居住在中低收入國家。此外，全球有5.41億成年人有葡萄糖耐受不良，這些人罹患第2型糖尿病的風險更高，這進一步擴大了可從血糖監測中獲益的目標人口。血糖監測系統是管理和預防糖尿病進展的重要工具，它使患者能夠監測和管理血糖值，並及時調整飲食、運動和藥物治療。對於葡萄糖耐受不良者，監測有助於及早發現血糖值波動，並支持採取乾預措施以預防糖尿病的發生。糖尿病和糖尿病前期患者群體龐大且持續成長，需要終身監測，成為市場成長最強勁的動力。

過渡到持續血糖監測

持續血糖監測 (SGL) 的加速普及是血糖監測系統市場的核心驅動力。這一趨勢推動了市場規模和市場價值的成長，患者從間歇性指尖採血測試轉向基於感測器的系統，後者提供更高的附加價值和持續的收入。 SGL 系統可進行即時和間歇性掃描，由於其比自我監測更高的準確性和便利性，其應用正在加速成長，從而提高了患者的依從性。 SGL 系統在最佳化治療方面發揮著重要作用，尤其是在胰島素依賴型患者中，這顯著提升了市場收入。 SGL 系統使用小型皮下植入感測器即時追蹤血糖值，透過測量組織液中的血糖值並每隔幾分鐘更新一次讀數，從而減少了頻繁手動檢查的需求。此外，它們還具有高血糖和低血糖警報、免校準技術以及與智慧型手機和數位健康平台的整合等功能，使其對 1 型和 2 型糖尿病患者尤其有益。這些系統透過與胰島素幫浦和自動胰島素輸注系統的整合，幫助患者更好地控制血糖，降低低血糖風險，並最佳化胰島素治療。它們也擴大應用於臨床研究，以探索血糖模式。儘管持續血糖監測能夠帶來卓越的治療效果和永續的收入模式，但其應用尚未完全普及，因此，向該領域的轉型將成為推動成長的強大且永續的動力。

市場限制因素

儘管糖尿病患者數量龐大且持續成長，技術也快速發展，但血糖監測系統市場仍面臨許多重大限制因素。其中最關鍵的是讀數不準確和技術故障的風險。血糖值測量不準確會導致胰島素劑量錯誤，進而引發低血糖或高血糖。這兩種情況都非常危險，甚至可能危及生命。此外，設備不準確造成的臨床影響也給製造商帶來了沉重的負擔，要求其確保設備的準確性和可靠性，這使得臨床醫生和患者在使用新設備時都持謹慎態度。感測器精度、校準、干擾以及組織液和血糖血糖值的延遲血糖值誤差來源。由於自動胰島素輸注依賴持續的血糖監測數據，因此準確性的重要性更加凸顯，因為讀數不準確會導致在無人干預的情況下進行不恰當的胰島素輸注。第二個限制因素是存在其他替代方案。患者和醫療系統可選擇的設備和監測策略種類繁多，而自我監測、間歇性掃描式連續血糖監測和即時連續血糖監測之間的競爭，加上低成本血糖儀和試紙的普及，限制了單一設備和製造商的定價權和終端用戶群。其他限制因素包括：與指尖採血檢測相比，連續血糖監測系統的高成本，這限制了其在沒有醫保覆蓋地區的使用；感測器和耗材的持續成本；不同市場和目標人群的醫保報銷情況各不相同；以及對某些患者而言，持續佩戴感測器會帶來不適、皮膚反應和負擔。這些與準確性、競爭和成本相關的因素共同推動了快速成長，但同時也面臨許多實際限制因素。

目錄

第1章：血糖監測系統市場：簡介

  • 調查範圍
  • 市場區隔
  • 市場概覽

第2章：血糖監測系統市場：摘要整理

  • 主要亮點和市場概覽

第3章：血糖監測系統市場：關鍵因素分析

  • 市場促進因素
    • 全球糖尿病盛行率正在上升。
    • 過渡到持續血糖監測
    • 感測器和連接技術的進步
    • 主要市場有利的贖回政策
  • 市場限制因素
    • 測量誤差和胰島素劑量誤差
    • 替代方案的可用性
    • 成本和保險報銷限制
  • 市場機遇
    • 數位健康解決方案的實施
    • 與智慧型手機、穿戴式裝置和物聯網裝置整合。

第4章：人工智慧、地緣政治、貿易與經濟趨勢

第5章：監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章：波特五力分析

第7章 血糖監測系統市場：評估

  • 依產品類型
    • 自我監測血糖系統
    • 連續血糖監測系統
  • 按模式
    • 穿戴式裝置
    • 不穿戴式
  • 最終用戶
    • 醫院
    • 居家醫療
    • 其他
  • 按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章：血糖監測系統市場：競爭格局

  • 競爭分析
  • 企業市場占有率分析（加值服務）

第9章 血糖監測系統市場：新創企業資金籌措與投資趨勢

第10章 血糖監測系統市場：公司概況與產品概況

  • Medtronic plc
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • LifeScan, Inc.
  • Dexcom, Inc.
  • ARKRAY, Inc.
  • Senseonics Holdings, Inc.
  • WaveForm Technologies, Inc.
  • B. Braun Melsungen AG
  • Ascensia Diabetes Care Holdings AG

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0013

Blood Glucose Monitoring Systems Market Summary

Overview:

  • The global blood glucose monitoring systems market was valued at USD 13.06 billion in 2025 and is projected to reach USD 25.50 billion by 2034.
  • The market is expected to expand at a CAGR of 7.72% during the forecast period 2026-2034, supported by the rising prevalence of lifestyle disorders such as diabetes and impaired glucose tolerance, growing product launches and approvals, and a rising preference for minimally invasive monitoring techniques.
  • By product type, the continuous glucose monitoring systems segment dominated the blood glucose monitoring systems market with a 62% share in 2025.
  • By modality, the wearable segment dominated the blood glucose monitoring systems market with a 58% share in 2025.
  • By end-user, the home care settings segment dominated the blood glucose monitoring systems market with a 60% share in 2025.
  • North America accounted for the largest share of the blood glucose monitoring systems market at 38% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Blood glucose monitoring systems are the devices used at home or in healthcare settings to measure and monitor the concentration of glucose in the blood, enabling people with diabetes and impaired glucose tolerance to track their levels and adjust diet, exercise, and medication accordingly. The market is organized by the type of device supplied, the modality of use, and the setting of care. By product type, it divides between self-monitoring blood glucose systems, in which the user obtains a reading from a drop of capillary blood on a test strip read by a meter, and continuous glucose monitoring systems, in which a small sensor placed under the skin measures glucose in the interstitial fluid and updates readings continuously. By modality, it divides between wearable devices, principally the sensor-based continuous and long-wear systems worn on the body, and non-wearable devices, principally the meters and test strips used for intermittent self-monitoring. By end-user, it spans hospitals, home care settings, and other settings in which glucose is measured and managed. The market is expanding rapidly, driven by the rising global prevalence of diabetes, the accelerating shift toward continuous glucose monitoring, continuous technological advancement in sensor accuracy, wear duration, connectivity, and artificial intelligence, and the integration of glucose data with digital health platforms and automated insulin delivery.

Blood Glucose Monitoring Systems Market Key Growth Drivers

  • The rising global prevalence of Type 1, Type 2, and gestational diabetes, with the International Diabetes Federation reporting that 537 million adults were living with diabetes in 2021, a figure projected to reach 643 million by 2030 and 783 million by 2045.
  • The accelerating shift toward continuous glucose monitoring, as real-time and intermittently scanned systems offer better accuracy, convenience, and adherence, particularly among insulin-dependent patients.
  • Continuous technological advancement, including improved sensor accuracy, longer wear durations, smartphone connectivity, cloud-based data sharing, artificial-intelligence-driven predictive insights, and minimally invasive and needle-free sensors.
  • Increasing awareness of early diagnosis and self-management, with self-monitoring of blood glucose, preventive care programs, and education initiatives encouraging regular monitoring.
  • Favorable reimbursement policies in major markets, since coverage for test strips, meters, and continuous glucose monitoring systems in the United States, Europe, and Japan reduces out-of-pocket costs and supports adoption.
  • The growth of the geriatric population, since older adults have a higher prevalence of diabetes and require continuous monitoring, increasing both self-monitoring and continuous glucose monitoring usage.
  • The integration of digital health platforms, including cloud-based data sharing, remote patient monitoring, telehealth, and physician dashboards, increases the value of the devices in chronic disease management.

Key Companies in Blood Glucose Monitoring Systems Market

The competitive landscape is led by the following active manufacturers:

  • Medtronic plc
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • LifeScan, Inc.
  • Dexcom, Inc.
  • ARKRAY, Inc.
  • Senseonics Holdings, Inc.
  • WaveForm Technologies, Inc.
  • B. Braun Melsungen AG
  • Ascensia Diabetes Care Holdings AG

Factors Contributing to the Growth of the Blood Glucose Monitoring Systems Market

Market Drivers

Rising Global Prevalence of Diabetes

The foundational driver of the blood glucose monitoring systems market is the rapidly increasing prevalence of diabetes, because the size of the diabetic population directly determines the demand for the meters, test strips, and continuous glucose monitoring systems that constitute the market. The rising incidence of Type 1, Type 2, and gestational diabetes is the strongest driver of demand, since a larger patient pool boosts the sale of every category of device, and the scale and trajectory of the burden are striking. The International Diabetes Federation reported that 537 million adults aged 20 to 79 were living with diabetes in 2021, equating to about one in ten individuals, and projected this number to rise to 643 million by 2030 and to 783 million by 2045, with over 75% of adults with diabetes residing in low- and middle-income countries. A further 541 million adults have impaired glucose tolerance, placing them at elevated risk of developing Type 2 diabetes and extending the population that benefits from monitoring. Blood glucose monitoring systems are essential tools for managing diabetes and preventing its progression, enabling individuals to check and manage their levels and make timely adjustments to diet, exercise, and medication. For those with impaired glucose tolerance, monitoring can identify early glucose fluctuations and support interventions to prevent the onset of diabetes. Because the diabetic and pre-diabetic population is very large, rising, and requires lifelong monitoring, this driver provides the most durable foundation for market growth.

Shift Toward Continuous Glucose Monitoring

The accelerating shift toward continuous glucose monitoring is a central driver of the blood glucose monitoring systems market, because it moves patients from intermittent finger-stick testing toward the sensor-based systems that command higher value and recurring revenue, raising both the volume and the value of the market. The adoption of real-time and intermittently scanned continuous glucose monitoring systems is accelerating due to their better accuracy, convenience, and improved patient adherence relative to self-monitoring, and their role in therapy optimization, especially among insulin-dependent patients, significantly increases market revenue. A continuous glucose monitoring system provides real-time tracking of glucose by using a small sensor placed under the skin to measure glucose in the interstitial fluid, updating readings every few minutes and reducing the need for frequent manual checks, and its features, including alarms for high or low glucose, calibration-free technology, and integration with smartphones and digital health platforms, make it particularly beneficial for people with Type 1 and Type 2 diabetes. These systems help patients achieve better glycemic control, reduce the risk of hypoglycemia, and optimize insulin therapy through integration with insulin pumps and automated insulin delivery systems, and they are increasingly used in clinical research to analyze glucose patterns. Because continuous glucose monitoring delivers superior outcomes and a recurring-revenue model, and because its adoption remains far from complete, the shift toward it is a powerful and durable driver of growth.

Market Restraints

Despite a large and rising diabetic population and rapid technological advances, the blood glucose monitoring systems market faces several material constraints. The most significant is the risk of false readings or technical errors, since an inaccurate glucose reading can lead to incorrect insulin dosing, which is associated with hypoglycemia or hyperglycemia, both of which are dangerous and potentially life-threatening, and the clinical consequences of device inaccuracy place a high burden of accuracy and reliability upon manufacturers and create caution among clinicians and patients in adopting new devices. Sensor accuracy, calibration, interference, and the lag between interstitial and blood glucose all contribute to the potential for error, and the reliance of automated insulin delivery upon continuous glucose monitoring data raises the stakes of accuracy further, since an erroneous reading can drive an inappropriate insulin dose without human intervention. A second constraint is the availability of alternative options, since patients and health systems can choose among a range of devices and monitoring strategies, and the competition among self-monitoring, intermittently scanned continuous monitoring, and real-time continuous monitoring, together with the availability of low-cost meters and strips, limits the pricing power and the end-user base of any individual device or manufacturer. Additional constraints include the high cost of continuous glucose monitoring systems relative to finger-stick testing, which limits access where reimbursement is unavailable; the recurring cost of sensors and consumables; the variability of reimbursement across markets and populations; and, for some patients, the discomfort, skin reactions, and burden of wearing a sensor continuously. Together, these accuracy, competitive, and cost factors ensure that growth, while rapid, proceeds against genuine constraint.

Blood Glucose Monitoring Systems Market Segment Analysis

The global blood glucose monitoring systems market by product type (self-monitoring blood glucose systems and continuous glucose monitoring systems), by modality (wearable and non-wearable), by end-user (hospitals, home care settings, and others), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Product Type

Dominant Subsegment: Continuous Glucose Monitoring Systems.

The continuous glucose monitoring systems segment accounted for a 62% share of the blood glucose monitoring systems market in 2025. Continuous glucose monitoring systems dominate the product-type structure owing to the key features and widespread application they provide and to the accelerating shift of patients from intermittent finger-stick testing toward sensor-based continuous monitoring. A continuous glucose monitoring system provides real-time tracking of glucose by using a small sensor placed under the skin to measure glucose in the interstitial fluid, updating readings every few minutes and reducing the need for frequent manual checks, and its features, including alarms for high or low glucose, calibration-free technology, and integration with smartphones and digital health platforms, deliver a level of information and convenience that finger-stick testing cannot match. These systems are especially beneficial for people with Type 1 and Type 2 diabetes, helping them achieve better glycemic control, reduce the risk of hypoglycemia, and optimize insulin therapy through integration with insulin pumps and automated insulin delivery, and they are widely used in clinical research to analyze glucose patterns. The higher price of continuous glucose monitoring systems and their recurring sensor revenue mean that the segment captures a disproportionate share of market value, and the wave of product launches and approvals, including over-the-counter systems that extend continuous monitoring beyond the insulin-using population, continues to expand it. Self-monitoring blood glucose systems constitute the second product category, comprising the meters and test strips used for intermittent testing, which remain widely used for their low cost and simplicity. Continuous glucose monitoring systems are expected to retain and extend their leading share throughout the forecast period.

By Modality

Dominant Subsegment: Wearable.

The wearable segment accounted for a 58% share of the blood glucose monitoring systems market in 2025. Wearable devices dominate the modality structure because the continuous glucose monitoring systems that increasingly define the market are worn on the body, and the migration toward continuous monitoring therefore drives the migration toward wearable devices. A wearable glucose monitoring device consists of a small sensor worn on the skin, typically on the upper arm or abdomen, that measures glucose in the interstitial fluid continuously and transmits the readings to a smartphone or reader, and this form factor is intrinsic to the continuous, real-time, and long-wear monitoring that delivers the superior glycemic control and convenience driving the market. The wearable modality has advanced rapidly, with sensors that last progressively longer, some approaching a full year of wear, that require no calibration or finger-stick confirmation, and that connect directly to smartphones and the cloud, and the extension of wearable continuous monitoring to the over-the-counter and wellness markets has broadened the wearable population beyond the insulin-using patients who pioneered it. The comfort, convenience, and continuous information that wearable sensors provide underpin the adherence and outcomes that make them the preferred modality. Non-wearable devices constitute the second modality, comprising the meters and test strips used for intermittent self-monitoring, which remain important for their low cost and simplicity, particularly in cost-sensitive and lower-intensity settings. Wearable devices are expected to retain and extend their leading share throughout the forecast period.

Blood Glucose Monitoring Systems Market Region Analysis

Dominant Region: North America

North America accounted for a 38% share of the global blood glucose monitoring systems market in 2025. The region is expected to dominate the blood glucose monitoring systems market throughout the forecast period, driven by the rising cases of diabetes, advancements in blood glucose monitoring systems, strong regulatory support, and the introduction of innovative products by the key market players. As per the Centers for Disease Control and Prevention, in 2021 some 38.4 million people of all ages, or 11.6% of the United States population, had diabetes, creating a very large monitoring population, and blood glucose monitoring systems are essential tools for managing that population, enabling users to track glucose fluctuations throughout the day and to make timely adjustments to diet, physical activity, and medication. The region combines the largest and most technologically advanced diabetes-care market in the world with strong reimbursement for meters, strips, and continuous glucose monitoring systems, a high rate of adoption of continuous and connected monitoring, and the presence and commercial strength of the leading manufacturers. The region also leads in the regulatory clearance and early launch of innovative products, including the over-the-counter continuous glucose monitoring systems and the disposable, all-in-one sensors that are extending the market beyond the insulin-using population, and the continuing flow of product development and approvals accelerates growth. The region is expected to retain its leading position throughout the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate in the blood glucose monitoring systems market through 2034. The region is emerging as the principal growth engine of the market, propelled by a very large and rapidly rising diabetic population, expanding healthcare access, rising awareness of diabetes management, and the increasing availability and affordability of both self-monitoring and continuous glucose monitoring systems. The region carries an enormous burden of diabetes, with the International Diabetes Federation identifying the largest and fastest-growing diabetic populations in the major Asian economies, and the combination of large populations, rising prevalence driven by urbanization and lifestyle change, and the concentration of much of the global diabetic population in the low- and middle-income countries of the region creates rapidly growing demand for monitoring. Expanding healthcare access, rising disposable incomes, growing awareness of the importance of glycemic control, and government initiatives to address the diabetes burden are converting this rising prevalence into demand for devices, and both international manufacturers and capable regional participants, including major domestic device companies, are expanding to serve the opportunity with products spanning the premium and cost-effective segments. China combines the largest diabetic population in the world with a rapidly developing domestic device industry, India combines a very large and rising diabetic population with expanding access, and Japan combines an aged population with sophisticated adoption of advanced monitoring. Regional growth is expected to exceed the global average across every segment.

Regional Commentary

North America

North America leads on value and adoption, holding a 38% share in 2025. The region combines the largest and most advanced diabetes-care market with strong reimbursement, high adoption of continuous and connected monitoring, and the commercial strength of the leading manufacturers. The Centers for Disease Control and Prevention reported some 38.4 million people, or 11.6% of the United States population, with diabetes in 2021, creating a very large monitoring population, and the region leads in the clearance and launch of innovative products including over-the-counter and disposable continuous glucose monitoring systems. Near-term dynamics are shaped by the shift to continuous monitoring, the extension of monitoring to the non-insulin and wellness populations, automated insulin delivery, and digital health integration.

Europe

Europe is a large and advanced market, home to several of the leading manufacturers and supported by well-developed public healthcare systems, broad reimbursement for continuous glucose monitoring, and high adoption of connected monitoring, with Germany, France, and the United Kingdom the principal markets. The region combines a substantial and aging diabetic population with generally supportive reimbursement and strong clinical adoption of continuous glucose monitoring, and it hosts major diabetes-care companies and the launch of new continuous monitoring systems. Reimbursement policy varies by country, and public budget constraints influence the pace and scale of adoption, but the region sustains a competitive and advanced market served by both global and regional participants.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a very large and rapidly rising diabetic population, expanding healthcare access, rising awareness, and the increasing availability and affordability of monitoring systems. The region carries an enormous and rising burden of diabetes, and expanding access, rising incomes, and government initiatives are converting prevalence into demand. China combines the largest diabetic population with a developing domestic device industry, India combines a very large and rising diabetic population with expanding access, and Japan combines an aged population with advanced adoption. Both international and regional manufacturers are expanding across the premium and cost-effective segments. Growth exceeds the global average across every segment.

Rest of World

The Rest of the World comprises the Middle East, Africa, and South America. The burden of diabetes is high and rising across all three, and the region carries a substantial share of the global diabetic population. The Gulf states combine a very high diabetes prevalence with advanced healthcare systems and high adoption of advanced monitoring, and the larger Latin American markets, particularly Brazil and Mexico, support substantial and growing diabetes-care markets, together representing steady growth. Much of Africa faces constrained healthcare access and affordability, so monitoring is concentrated in the larger urban and private markets. Regional growth will be driven by the rising diabetes burden, expanding healthcare access, growing awareness, and the availability of cost-appropriate self-monitoring and continuous monitoring systems from international and regional manufacturers.

Blood Glucose Monitoring Systems Market Competitive Landscape

The global blood glucose monitoring systems market is classified as Moderately Consolidated. The market is led by a group of large diabetes-care and medical technology companies with established meter, test strip, and continuous glucose monitoring franchises, which hold the largest combined share and dictate industry trends, complemented by specialized sensor and continuous-monitoring innovators. Competition centers upon the accuracy, wear duration, and convenience of the sensor, the breadth of the device and consumables portfolio, integration with automated insulin delivery and digital health platforms, reimbursement standing, and increasingly upon the extension of continuous monitoring to new populations. The competitive landscape is evaluated across the following dimensions:

  • Market concentration: Moderately consolidated, with a group of large diabetes-care and medical technology companies holding the largest combined share across the meter, strip, and continuous glucose monitoring categories alongside specialized sensor and continuous-monitoring innovators, and with the sensor technology, clinical evidence, and reimbursement standing of the leaders constituting a barrier to entry.
  • Leading players: The continuous glucose monitoring segment is led by Abbott and Dexcom, with Medtronic strong in continuous monitoring integrated with insulin pumps and automated insulin delivery, while Roche, LifeScan, Ascensia, ARKRAY, and i-SENS lead the self-monitoring meter and test strip segment, and Senseonics contests the long-wear implantable continuous monitoring niche.
  • Geographic reach: The leading participants maintain global commercial and distribution organizations, which matter because monitoring is a mass-market chronic-disease category requiring broad reach and local reimbursement, while regional manufacturers, particularly the major Chinese and Korean device companies, serve domestic and cost-sensitive markets, and the over-the-counter channel extends reach to the consumer and wellness populations.
  • Product portfolio strength: Competitive advantage rests upon the accuracy, wear duration, and convenience of the continuous glucose monitoring sensor, the breadth of the portfolio across continuous and self-monitoring and across insulin-using and non-insulin populations, and the integration with automated insulin delivery and digital health platforms, since patients, clinicians, and payers value accurate, convenient, connected, and clinically proven systems.
  • Pipeline strength: Development is concentrated in longer-wear and calibration-free sensors, needle-free and non-invasive monitoring, over-the-counter and wellness continuous monitoring, integration with automated insulin delivery and the artificial pancreas, and artificial-intelligence-driven predictive analytics and coaching.
  • Strategic partnerships: Collaboration spans partnerships between device manufacturers, digital health companies, and cloud-platform providers to enhance remote monitoring, data analytics, and decision support, and integration partnerships between continuous glucose monitoring and insulin pump and automated insulin delivery companies to build closed-loop systems.
  • M&A activity: Acquisition activity centers upon the strengthening of continuous monitoring, sensor, and digital health capability, including the acquisition of diabetes-focused digital health startups and sensor technology firms to build portfolios in continuous monitoring, wearable devices, and artificial-intelligence-enabled glucose management.
  • Innovation focus: Innovation is shifting toward needle-free and implantable sensors, integration with artificial-intelligence algorithms for predictive glucose alerts, cloud-linked monitoring ecosystems, fully automated closed-loop insulin delivery, and the extension of continuous monitoring to the over-the-counter, wellness, and non-insulin populations.
  • Regulatory standing: Regulatory clearance and, decisively, reimbursement standing are operative credentials, since the accuracy requirements of glucose monitoring and its use in insulin dosing demand rigorous clearance, and the extension of coverage to broader populations and the clearance of over-the-counter systems are significant competitive factors, alongside the integrated continuous glucose monitoring designation that permits use in automated insulin delivery.

Blood Glucose Monitoring Systems Market Recent Developmental Activities

In August 2025, Signos launched the Signos Glucose Monitoring System, the first over-the-counter glucose monitoring system cleared by the United States Food and Drug Administration and designed for weight management, integrating the Stelo by Dexcom glucose biosensor with an artificial-intelligence-powered platform that provides personalized, real-time insights into how food, activity, stress, and sleep affect metabolic health. Strategic significance: the extension of continuous glucose monitoring into over-the-counter weight management illustrated the broadening of the market beyond diabetes into metabolic health and wellness, opening a large new non-insulin population to sensor-based monitoring.

Blood Glucose Monitoring Systems Market Segmentation

Blood Glucose Monitoring Systems Market Assessment by Product Type

  • Self-Monitoring Blood Glucose Systems
  • Continuous Glucose Monitoring Systems

Blood Glucose Monitoring Systems Market Assessment by Modality

  • Wearable
  • Non-Wearable

Blood Glucose Monitoring Systems Market Assessment by End-User

  • Hospitals
  • Home Care Settings
  • Others

Blood Glucose Monitoring Systems Market Assessment by Geography

  • North America
  • United States Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Canada Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Mexico Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Europe
  • France Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Germany Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • United Kingdom Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Italy Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Spain Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Rest of Europe Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Asia-Pacific
  • China Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Japan Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • India Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Australia Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • South Korea Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Rest of the World
  • Middle East Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Africa Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • South America Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)

Frequently Asked Questions:

Q1. At what rate is the blood glucose monitoring systems market expected to grow?

The global blood glucose monitoring systems market is projected to grow at a compound annual growth rate of 7.72% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the blood glucose monitoring systems market?

The global blood glucose monitoring systems market was valued at USD 13.06 billion in 2025 and is projected to reach USD 25.50 billion by 2034.

Q3. Which region dominates the blood glucose monitoring systems market?

North America dominated the blood glucose monitoring systems market with a 38% share in 2025, driven by the rising cases of diabetes, advancement in monitoring systems, strong regulatory support, and the introduction of innovative products, with the Centers for Disease Control and Prevention reporting some 38.4 million people, or 11.6% of the United States population, with diabetes in 2021. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by a very large and rapidly rising diabetic population, expanding healthcare access, rising awareness, and the increasing availability and affordability of monitoring systems.

Q4. What are the key factors driving growth in the blood glucose monitoring systems market?

The principal drivers are the rising global prevalence of diabetes, with the International Diabetes Federation reporting 537 million adults living with diabetes in 2021, rising to a projected 643 million by 2030 and 783 million by 2045; the accelerating shift toward continuous glucose monitoring; continuous technological advancement in sensor accuracy, wear duration, connectivity, and artificial intelligence; increasing awareness of early diagnosis and self-management; favorable reimbursement policies in the United States, Europe, and Japan; the growth of the geriatric population; and the integration of digital health platforms.

Q5. Who are the major players in the blood glucose monitoring systems market?

The market is moderately consolidated and led by Medtronic plc, Abbott Laboratories, F. Hoffmann-La Roche Ltd., LifeScan, Inc., and Dexcom, Inc., with the continuous glucose monitoring segment led by Abbott and Dexcom and the self-monitoring segment led by Roche, LifeScan, and Ascensia. Additional participants include ARKRAY, Inc., Senseonics Holdings, Inc., WaveForm Technologies, Inc., B. Braun Melsungen AG, Ascensia Diabetes Care Holdings AG, Ypsomed, i-SENS, Inc., Intuity Medical, Inc., ACON Laboratories, Inc., Sinocare, Menarini Diagnostics s.r.l., Bionime Corporation, and Nemaura Medical.

Table of Contents

1. Blood Glucose Monitoring Systems Market Introduction

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Market Overview at a Glance

2. Blood Glucose Monitoring Systems Market Executive Summary

  • 2.1. Key Highlights and Market Snapshot

3. Blood Glucose Monitoring Systems Market Key Factors Analysis

  • 3.1. Market Drivers
    • 3.1.1. Rising Global Prevalence of Diabetes
    • 3.1.2. Shift Toward Continuous Glucose Monitoring
    • 3.1.3. Technological Advancement in Sensors and Connectivity
    • 3.1.4. Favorable Reimbursement Policies in Major Markets
  • 3.2. Market Restraints
    • 3.2.1. False Readings and Incorrect Insulin Dosing
    • 3.2.2. Availability of Alternative Options
    • 3.2.3. Cost and Reimbursement Constraints
  • 3.3. Market Opportunities
    • 3.3.1. Adoption of Digital Health Solutions
    • 3.3.2. Integration with Smartphones, Wearables, and IoT Devices

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1. The United States
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. China

6. Blood Glucose Monitoring Systems Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Blood Glucose Monitoring Systems Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Self-Monitoring Blood Glucose Systems
    • 7.1.2. Continuous Glucose Monitoring Systems
  • 7.2. By Modality
    • 7.2.1. Wearable
    • 7.2.2. Non-Wearable
  • 7.3. By End-User
    • 7.3.1. Hospitals
    • 7.3.2. Home Care Settings
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.1.2. Canada Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.1.3. Mexico Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
    • 7.4.2. Europe
      • 7.4.2.1. France Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.2.2. Germany Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.2.3. United Kingdom Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.2.4. Italy Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.2.5. Spain Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.2.6. Rest of Europe Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.3.2. Japan Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.3.3. India Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.3.4. Australia Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.3.5. South Korea Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.3.6. Rest of Asia-Pacific Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
    • 7.4.4. Rest of the World
      • 7.4.4.1. Middle East Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.4.2. Africa Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
      • 7.4.4.3. South America Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)

8. Blood Glucose Monitoring Systems Market Competitive Landscape

  • 8.1. Competitive Analysis
  • 8.2. Company Share Analysis (Premium Offering)

9. Blood Glucose Monitoring Systems Market Startup Funding and Investment Trends

10. Blood Glucose Monitoring Systems Market Company and Product Profiles

  • 10.1. Medtronic plc
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Financial Overview
    • 10.1.4. Product Listing
    • 10.1.5. Strategic Initiatives / Entropy
  • 10.2. Abbott Laboratories
    • 10.2.1. Company Overview
    • 10.2.2. Company Snapshot
    • 10.2.3. Financial Overview
    • 10.2.4. Product Listing
    • 10.2.5. Strategic Initiatives / Entropy
  • 10.3. F. Hoffmann-La Roche Ltd.
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Financial Overview
    • 10.3.4. Product Listing
    • 10.3.5. Strategic Initiatives / Entropy
  • 10.4. LifeScan, Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Company Snapshot
    • 10.4.3. Financial Overview
    • 10.4.4. Product Listing
    • 10.4.5. Strategic Initiatives / Entropy
  • 10.5. Dexcom, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Company Snapshot
    • 10.5.3. Financial Overview
    • 10.5.4. Product Listing
    • 10.5.5. Strategic Initiatives / Entropy
  • 10.6. ARKRAY, Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Company Snapshot
    • 10.6.3. Financial Overview
    • 10.6.4. Product Listing
    • 10.6.5. Strategic Initiatives / Entropy
  • 10.7. Senseonics Holdings, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Company Snapshot
    • 10.7.3. Financial Overview
    • 10.7.4. Product Listing
    • 10.7.5. Strategic Initiatives / Entropy
  • 10.8. WaveForm Technologies, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Company Snapshot
    • 10.8.3. Financial Overview
    • 10.8.4. Product Listing
    • 10.8.5. Strategic Initiatives / Entropy
  • 10.9. B. Braun Melsungen AG
    • 10.9.1. Company Overview
    • 10.9.2. Company Snapshot
    • 10.9.3. Financial Overview
    • 10.9.4. Product Listing
    • 10.9.5. Strategic Initiatives / Entropy
  • 10.10. Ascensia Diabetes Care Holdings AG
    • 10.10.1. Company Overview
    • 10.10.2. Company Snapshot
    • 10.10.3. Financial Overview
    • 10.10.4. Product Listing
    • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Global Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Table 2: Global Blood Glucose Monitoring Systems Market Size by Product Type in USD million (2023-2034)
  • Table 3: Global Blood Glucose Monitoring Systems Market Size by Modality in USD million (2023-2034)
  • Table 4: Global Blood Glucose Monitoring Systems Market Size by End-User in USD million (2023-2034)
  • Table 5: Blood Glucose Monitoring Systems Market Size in North America in USD million (2023-2034)
  • Table 6: Blood Glucose Monitoring Systems Market Size in the United States in USD million (2023-2034)
  • Table 7: Blood Glucose Monitoring Systems Market Size in Canada in USD million (2023-2034)
  • Table 8: Blood Glucose Monitoring Systems Market Size in Mexico in USD million (2023-2034)
  • Table 9: Blood Glucose Monitoring Systems Market Size in Europe in USD million (2023-2034)
  • Table 10: Blood Glucose Monitoring Systems Market Size in France in USD million (2023-2034)
  • Table 11: Blood Glucose Monitoring Systems Market Size in Germany in USD million (2023-2034)
  • Table 12: Blood Glucose Monitoring Systems Market Size in the United Kingdom in USD million (2023-2034)
  • Table 13: Blood Glucose Monitoring Systems Market Size in Italy in USD million (2023-2034)
  • Table 14: Blood Glucose Monitoring Systems Market Size in Spain in USD million (2023-2034)
  • Table 15: Blood Glucose Monitoring Systems Market Size in the Rest of Europe in USD million (2023-2034)
  • Table 16: Blood Glucose Monitoring Systems Market Size in Asia-Pacific in USD million (2023-2034)
  • Table 17: Blood Glucose Monitoring Systems Market Size in China in USD million (2023-2034)
  • Table 18: Blood Glucose Monitoring Systems Market Size in Japan in USD million (2023-2034)
  • Table 19: Blood Glucose Monitoring Systems Market Size in India in USD million (2023-2034)
  • Table 20: Blood Glucose Monitoring Systems Market Size in Australia in USD million (2023-2034)
  • Table 21: Blood Glucose Monitoring Systems Market Size in South Korea in USD million (2023-2034)
  • Table 22: Blood Glucose Monitoring Systems Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Table 23: Blood Glucose Monitoring Systems Market Size in the Rest of the World in USD million (2023-2034)
  • Table 24: Blood Glucose Monitoring Systems Market Size in the Middle East in USD million (2023-2034)
  • Table 25: Blood Glucose Monitoring Systems Market Size in Africa in USD million (2023-2034)
  • Table 26: Blood Glucose Monitoring Systems Market Size in South America in USD million (2023-2034)
  • Table 27: Blood Glucose Monitoring Systems Market Competitive Landscape
  • Table 28: Blood Glucose Monitoring Systems Market Startup Funding and Investment Trends

List of Figures

  • Figure 1: Blood Glucose Monitoring Systems Market Drivers
  • Figure 2: Blood Glucose Monitoring Systems Market Restraints
  • Figure 3: Blood Glucose Monitoring Systems Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis of the Blood Glucose Monitoring Systems Market (the United States)
  • Figure 6: Regulatory Analysis of the Blood Glucose Monitoring Systems Market (Europe)
  • Figure 7: Regulatory Analysis of the Blood Glucose Monitoring Systems Market (Japan)
  • Figure 8: Regulatory Analysis of the Blood Glucose Monitoring Systems Market (China)
  • Figure 9: Porter's Five Forces Analysis of the Blood Glucose Monitoring Systems Market
  • Figure 10: Competitive Analysis of the Blood Glucose Monitoring Systems Market
  • Figure 11: Global Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
  • Figure 12: Global Blood Glucose Monitoring Systems Market Size by Product Type in USD million (2023-2034)
  • Figure 13: Global Blood Glucose Monitoring Systems Market Size by Modality in USD million (2023-2034)
  • Figure 14: Global Blood Glucose Monitoring Systems Market Size by End-User in USD million (2023-2034)
  • Figure 15: Blood Glucose Monitoring Systems Market Size in North America in USD million (2023-2034)
  • Figure 16: Blood Glucose Monitoring Systems Market Size in the United States in USD million (2023-2034)
  • Figure 17: Blood Glucose Monitoring Systems Market Size in Canada in USD million (2023-2034)
  • Figure 18: Blood Glucose Monitoring Systems Market Size in Mexico in USD million (2023-2034)
  • Figure 19: Blood Glucose Monitoring Systems Market Size in Europe in USD million (2023-2034)
  • Figure 20: Blood Glucose Monitoring Systems Market Size in France in USD million (2023-2034)
  • Figure 21: Blood Glucose Monitoring Systems Market Size in Germany in USD million (2023-2034)
  • Figure 22: Blood Glucose Monitoring Systems Market Size in the United Kingdom in USD million (2023-2034)
  • Figure 23: Blood Glucose Monitoring Systems Market Size in Italy in USD million (2023-2034)
  • Figure 24: Blood Glucose Monitoring Systems Market Size in Spain in USD million (2023-2034)
  • Figure 25: Blood Glucose Monitoring Systems Market Size in the Rest of Europe in USD million (2023-2034)
  • Figure 26: Blood Glucose Monitoring Systems Market Size in Asia-Pacific in USD million (2023-2034)
  • Figure 27: Blood Glucose Monitoring Systems Market Size in China in USD million (2023-2034)
  • Figure 28: Blood Glucose Monitoring Systems Market Size in Japan in USD million (2023-2034)
  • Figure 29: Blood Glucose Monitoring Systems Market Size in India in USD million (2023-2034)
  • Figure 30: Blood Glucose Monitoring Systems Market Size in Australia in USD million (2023-2034)
  • Figure 31: Blood Glucose Monitoring Systems Market Size in South Korea in USD million (2023-2034)
  • Figure 32: Blood Glucose Monitoring Systems Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Figure 33: Blood Glucose Monitoring Systems Market Size in the Rest of the World in USD million (2023-2034)
  • Figure 34: Blood Glucose Monitoring Systems Market Size in the Middle East in USD million (2023-2034)
  • Figure 35: Blood Glucose Monitoring Systems Market Size in Africa in USD million (2023-2034)
  • Figure 36: Blood Glucose Monitoring Systems Market Size in South America in USD million (2023-2034)
  • Figure 37: Blood Glucose Monitoring Systems Market Competitive Landscape
  • Figure 38: Blood Glucose Monitoring Systems Market Startup Funding and Investment Trends